Currently, clinical trials evaluating tolerogenic DC for the treatment of autoimmune disease and prevention of graft rejection have mainly utilised peripheral blood monocyte’s, cultured in the presence of GM-CSF and IL-4 [reviewed in ref (58)]. Here, CSF2 is linked to autoimmune disease.